scispace - formally typeset
K

Kyle Concannon

Researcher at Harvard University

Publications -  9
Citations -  2123

Kyle Concannon is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 3, co-authored 3 publications receiving 1844 citations.

Papers
More filters
Journal ArticleDOI

Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition

TL;DR: A role for EMT in the blood-borne dissemination of human breast cancer is supported as both single cells and multicellular clusters, expressing known EMT regulators, including transforming growth factor (TGF)–β pathway components and the FOXC1 transcription factor.
Journal ArticleDOI

Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways

TL;DR: Observations point to a physiological feedback mechanism that attenuates oncogene addiction-mediated cell death associated with the withdrawal of growth factor signaling and may therefore contribute to the development of resistance.
Journal ArticleDOI

Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control.

TL;DR: In this paper , the molecular consequences of targeted DNA-damage response inhibition, from tumor cell death to increased engagement of the anti-tumor immune response, are discussed and mechanistic and clinical rationale for pairing targeted DDRis with immunotherapy for enhanced tumor control.
Proceedings ArticleDOI

Abstract A75: Circulating tumor cells in human breast cancer exhibit dynamic changes in epithelial and mesenchymal composition

TL;DR: Analysis of treatment responses in 10 patients suggested an association of mesenchymal CTCs with disease progression, and RNA sequencing of CTC clusters identified EMT-related signatures, including FOXC1, a known transcriptional regulator of EMT.